Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TTCCs were upregulated in PCas harboring androgen receptor (AR) mutations; CNV rate was positively associated with PCa progression.
|
31334879 |
2019 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia.
|
15824176 |
2005 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we report exclusive cytoplasmic actions of a splicing variant of the AR detected in a metastatic prostate cancer.
|
17540719 |
2007 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we report the characteristics of a novel AR mutation A748T located in helix 5 of the ligand-binding domain, which was identified in metastatic prostate cancer.
|
12456791 |
2002 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While modern therapies for metastatic prostate cancer (PCa) have improved survival they are associated with an increasingly prevalent entity, aggressive variant PCa (AVPCa), lacking androgen receptor (AR) expression, enriched for cancer stem cells (CSCs), and evidencing epithelial-mesenchymal plasticity with a varying extent of neuroendocrine transdifferentiation.
|
28103576 |
2017 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We apply our method to non-recurrent primary and metastatic prostate cancer data, and identify the androgen receptor gene (AR) among the top genetic mediators and the AR pathway as a highly enriched pathway for metastatic prostate cancer.
|
17299418 |
2007 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a specimen derived from metastatic prostate cancer we have reported a point mutation in the AR gene that leads to a single amino acid exchange in the ligand binding domain of the receptor.
|
8907206 |
1996 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This same AR mutation has been reported previously in a metastatic prostate cancer cell line, LNCaP, where this mutation confers upon the AR an altered ligand-binding specificity which is stimulated by estrogens, progestagens, and antiandrogens.
|
8187068 |
1994 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
|
11803263 |
2002 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
|
28925066 |
2017 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A consistent finding is that androgen receptor (AR) gene mutations, present in metastatic prostate cancer and in human prostate cancer cell lines as well as in xenograft and other animal models, result in decreased specificity of ligand-binding and inappropriate receptor activation by estrogens, progestins, adrenal androgens, glucocorticoids and/or AR antagonists.
|
11350894 |
2001 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.
|
31117038 |
2019 |
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer.
|
30135575 |
2018 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
|
21799031 |
2011 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used probe combinations that included the androgen receptor (AR) and MYC genes for FISH analysis of CTC samples collected from 77 men with castration-resistant metastatic prostate cancer.
|
19276271 |
2009 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As second-generation androgen receptor antagonists have been increasingly used for treatment of castration-resistant stage metastatic prostate cancer, new onset of symptomatic epidural lipomatosis should be considered as a possible differential diagnosis, especially because the urinary symptoms of cauda equina compression may be improperly attributed to the primary prostate neoplasm.
|
30763756 |
2019 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
|
26364608 |
2016 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two features of the progression from organ-confined to metastatic prostate cancer are dysregulation of the androgen receptor (AR) and a decrease in insulin-like growth factor-type-I receptor (IGF-IR) expression.
|
15368471 |
2004 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC).
|
29017058 |
2017 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel AR signaling pathway that induces microRNA-1 (miR-1) to suppress metastatic prostate cancer was recently demonstrated (AR-miR-1 signaling axis), and its regulation of Wnt signaling was explored in the current study.
|
28220803 |
2017 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
|
15774258 |
2005 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed outcomes in men with low prostate specific antigen and a high disease burden who received the oral androgen receptor inhibitor enzalutamide in the PREVAIL (Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer) study.
|
28736322 |
2017 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
|
27733296 |
2017 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively.
|
22767266 |
2012 |
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors usually develop resistance (castration-resistant PCa [CRPC]), but remain androgen receptor (AR) dependent.
|
26378018 |
2015 |